Carisma Therapeutics (United States)
- Research works
- 25 fractional, all time
- Citations
- 588 23.7 per fractional work
- Top-10% rate
- 10.3% record average 16.5%
- Open access
- 72% world 28%
Not ranked overall: Carisma Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Who are the top researchers at Carisma Therapeutics (United States)?
Ranked on the composite score, Michael Klichinsky lead among researchers whose main affiliation is Carisma Therapeutics (United States).
- 1 Michael Klichinsky United States · #218,441 worldwide 243 citations · 17 works
Which keywords describe research at Carisma Therapeutics (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Cancer Immunotherapy, Immunotherapy, CAR T Cells, Chimeric Antigen Receptor, Immunity, Cancer, Inflammation and Activation.
- Fc Receptors
- Tumor Microenvironment
- Dendritic Cells
- apoptotic cells
- Immune Regulation
- Activation
- Cancer
- Chimeric Antigen Receptor
- Immunotherapy
- Cancer Immunotherapy
- CAR T Cells
- Immunity
- Inflammation
- Macrophage
- CD47
- Antigen Presentation
- Innate Immunity
- Monoclonal Antibodies
- Therapeutic Antibodies
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 19 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 19 words, with their numbers
- Cancer Immunotherapy11▲ 329×3 topics
- Immunotherapy8▲ 50×6 topics
- CAR T Cells7▲ 642×1 topic
- Chimeric Antigen Receptor7▲ 642×1 topic
- Immunity6▲ 68×3 topics
- Cancer4▲ 12×3 topics
- Inflammation4▲ 7.3×4 topics
- Activation4▲ 430×1 topic
- Macrophage4▲ 267×1 topic
- Immune Regulation3▲ 91×2 topics
- CD473▲ 702×1 topic
- apoptotic cells3▲ 702×1 topic
- Antigen Presentation2▲ 75×1 topic
- Dendritic Cells2▲ 65×1 topic
- Innate Immunity2▲ 22×2 topics
- Tumor Microenvironment2▲ 21×4 topics
- Monoclonal Antibodies2▲ 47×2 topics
- Fc Receptors1▲ 58×1 topic
- Therapeutic Antibodies1▲ 45×1 topic
Which research topics does Carisma Therapeutics (United States) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, Immune cells in cancer, Immunotherapy and Immune Responses and Phagocytosis and Immune Regulation.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 3 works
- 2 Immune cells in cancer Immunology 2 works
- 3 Immunotherapy and Immune Responses Immunology 1 works
- 4 Phagocytosis and Immune Regulation Immunology 1 works
- 5 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 6 Cancer Immunotherapy and Biomarkers Oncology 0 works
- 7 RNA Interference and Gene Delivery Molecular Biology 0 works
- 8 Optical Coherence Tomography Applications Biomedical Engineering 0 works
- 9 Advanced Fluorescence Microscopy Techniques Biophysics 0 works
- 10 Reproductive System and Pregnancy Immunology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Carisma Therapeutics (United States)'s research output changed?
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Philadelphia
- University of Pennsylvania
- Temple University
- Drexel University
- Thomas Jefferson University
- Children's Hospital of Philadelphia
- Philadelphia University
- Hospital of the University of Pennsylvania
- Fox Chase Cancer Center
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.